Exchange: NASDAQ·Updated 04:35 PM EST

VRCA News

News
all
press releases
Verrica Pharmaceuticals Q2 2026 Earnings Call Transcript
Verrica Pharmaceuticals (NASDAQ:VRCA) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financialread more...
Benzinga
Verrica Pharmaceuticals Q2 2026 Earnings Call Transcript
Verrica Pharmaceuticals (NASDAQ:VRCA) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financialread more...
Benzinga
More News
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +14.29% and +1.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +30.51% and +6.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Lipocine (LPCN) delivered earnings and revenue surprises of -5.88% and +19.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Neurocrine (NBIX) delivered earnings and revenue surprises of +15.31% and +9.80%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Verrica Pharmaceuticals (NASDAQ:VRCA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 581,329 shares, a growth of 16.8% from the March 31st total of 497,753 shares. Based on an average...
MarketBeat
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has earned an average rating of "Reduce" from the four ratings firms that are currently covering the company, MarketBeat.com reports. Two...
MarketBeat
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 478,579 shares, a growth...
MarketBeat

Advertisement|Remove ads.